Physician profile
Robert B Guss
NPI 1457445553
$838.85
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $112 · 2021: $103 · 2022: $30.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $163.64 | 2019 | |
| Allergan, INC. | $136.14 | 2019-2020 | |
| Rxsight INC | $134.10 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $124.95 | 2019 | |
| Alcon Vision LLC | $120.39 | 2019 | |
| Hoffmann-La Roche Limited | $68.46 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.74 | 2019 | |
| Maculogix, INC. | $33.66 | 2019 | |
| Halozyme INC | $12.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Guss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.